Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them ...

A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...